potentially expanding the market for GLP-1 therapies. The company’s focus on developing treatments for related conditions, such as NASH (non-alcoholic steatohepatitis), could also open up new ...
potentially expanding the market for GLP-1 therapies. The company’s focus on developing treatments for related conditions, such as NASH (non-alcoholic steatohepatitis), could also open up new revenue ...
Zacks Investment Research on MSN2d
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharmaShares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown ... which is also known as non-alcoholic steatohepatitis (NASH). The results come from Part 1 of the ESSENCE trial, which involved ...
Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient. Secures Dedicated Fill/Finish Capacity for 100 Million Annua ...
VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent ... confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the ...
an antibody developed by NGM that could be used in NASH and type 2 diabetes. J&J handed back rights to Hanmi after efinopegdutide, a once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor ...
NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...
As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...
For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback